<div id="readability-page-1"><p><strong>AstraZeneca PLC</strong> (NASDAQ:AZN - Get Free Report) announced a  dividend on Tuesday, February 10th. Shareholders of record on Friday, February 20th will be given a dividend of 1.595 per share on Monday, March 23rd. The ex-dividend date is Friday, February 20th.</p><ul><li>Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All</li></ul><p>AstraZeneca has increased its dividend by an average of 0.0%per year over the last three years. AstraZeneca has a dividend payout ratio of 39.7% indicating that its dividend is sufficiently covered by earnings. Research analysts expect AstraZeneca to earn $5.00 per share next year, which means the company should continue to be able to cover its $2.02 annual dividend with an expected future payout ratio of 40.4%. </p><h2>AstraZeneca Trading Up 3.0%</h2><p>AstraZeneca stock traded up $5.60 during mid-day trading on Tuesday, hitting $193.61. The company's stock had a trading volume of 1,585,837 shares, compared to its average volume of 4,269,538. The company has a 50 day moving average of $103.79 and a 200-day moving average of $89.45. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. The stock has a market cap of $300.27 billion, a PE ratio of 64.31, a P/E/G ratio of 1.59 and a beta of 0.34. AstraZeneca has a one year low of $122.48 and a one year high of $195.90. </p><h2>More AstraZeneca News</h2><ul><li>How Does D-Wave Stack Up Against Quantum Competitors?</li></ul><p>Here are the key news stories impacting AstraZeneca this week:</p><ul>   <li><span>Positive Sentiment: </span>AstraZeneca forecast mid-to-high single‑digit revenue growth and low‑double‑digit core EPS growth for 2026, giving the market confidence in ongoing top‑line and profit expansion driven by oncology and CV medicines. Read More.</li>    <li><span>Positive Sentiment: </span>Full‑year 2025 results showed revenue up ~8% (to $58.7B) with product sales rising ~9%, reinforcing that the company’s growth engine and pipeline delivery are translating into durable sales. This supports the longer‑term revenue target cited by management. Read More.</li>    <li><span>Positive Sentiment: </span>AstraZeneca announced a dividend of $1.595 per share (record Feb 20, pay Mar 23), which is supportive for income investors and can help underpin demand for the stock. (Company release)</li>    <li><span>Positive Sentiment: </span>Q4 revenue of about $15.5B came in slightly ahead at constant currency and was supported by cancer drug sales, which management highlighted as a growth driver — a near‑term sales beat that eased investor concerns. Read More.</li>    <li><span>Neutral Sentiment: </span>Analyst and media write‑ups provide deeper metric analysis and quarter snapshots; these detail where results met or lagged expectations and help investors parse one‑time items, FX effects and margin/cost dynamics. Read More. Read More.</li>    <li><span>Negative Sentiment: </span>Zacks notes AstraZeneca missed Q4 EPS and sales estimates, a weakness that could concern short‑term traders and suggests some near‑term margin or timing pressures despite the strong guidance. Read More.</li> </ul><h2>AstraZeneca Company Profile</h2> (Get Free Report)<p>AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden's Astra AB and the UK's Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca's operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.  </p><ul><li>Tempus AI Stock: Time to Double Down or Cut and Run?</li></ul><p>The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than AstraZeneca</li><li>They’ve Built Major Gold Stories Before - And They’re Doing It Again</li><li>Nvidia CEO Issues Bold Tesla Call</li><li>Gold’s rally is big — but what comes next could be bigger</li><li>How to collect $500-$800 weekly (BlackRock's system)</li><li>Trump’s AI Secret: 100X Faster Than Nvidia</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/DividendChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVpO?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/DividendChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVpO"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AstraZeneca Right Now?</h2><p>Before you consider AstraZeneca, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.</p><p>While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>AstraZeneca PLC (NASDAQ:AZN) announced a dividend of $1.595 per share, payable on March 23rd to shareholders of record on February 20th. The ex-dividend date is also February 20th. The company has a dividend payout ratio of 39.7%, indicating earnings sufficiently cover the dividend. AstraZeneca's stock rose 3.0% to $193.61, with a market cap of $300.27 billion. Analysts expect earnings of $5.00 per share next year, supporting the dividend. Despite missing Q4 EPS and sales estimates, AstraZeneca forecasts mid-to-high single-digit revenue growth through 2026.</p>

Market Beat

SPDR S&P Biotech

AstraZeneca PLC ADRhedged

AstraZeneca

VanEck Biotech ETF

VG Health

iShares Global Healthcare

ALPS Medical Breakthrough

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

iShares US Pharma

AstraZeneca PLC (NASDAQ:AZN) Announces Dividend of 1.60